9 Enrolled - Novartis AQUARIUS

In this trial with Novartis, many patients screened for the study but were excluded for medical history reasons found only during the angiogram or other follow-up procedures performed after patients signed consent. Thus 30 patients were screened, and 9 randomized. This was our first trial performed in conjunction with a cath-lab, which also proved to be a monumental success for our team back in the summer of 2009. 

 A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy